Lenalidomide May Be Effective for Lymphoma Ineligible for Intensive Chemo, HCT

Share this content:
Lenalidomide may be safe and effective for patients with relapsed or refractory mantle cell lymphoma ineligible to receive intensive chemotherapy.
Lenalidomide may be safe and effective for patients with relapsed or refractory mantle cell lymphoma ineligible to receive intensive chemotherapy.

Lenalidomide may be safe and effective for patients with relapsed or refractory mantle cell lymphoma ineligible to receive intensive chemotherapy or hematopoietic cell transplantation (HCT) compared with investigator's choice of monotherapy, a study published in the journal The Lancet Oncology has shown.1

Lenalidomide is a thalidomide analogue already indicated for the treatment of patients with mantle cell lymphoma whose disease has relapsed or progressed after 2 prior therapies, including bortezomib. For this phase 2 study, researchers sought to evaluate the efficacy and safety of lenalidomide vs investigator's choice of single-agent therapy in the relapsed or refractory setting.

In the SPRINT trial, researchers enrolled 254 patients with relapsed or refractory mantle cell lymphoma who were ineligible to undergo intensive chemotherapy or HCT and had an ECOG performance status of 0 to 2. Patients had received a median of 2 previous regimens.

Participants were randomly assigned 2:1 to receive lenalidomide 25 mg orally on days 1-21 every 28 days until disease progression or unacceptable toxicity, or single-agent investigator's choice of chlorambucil, cytarabine, fludarabine, gemcitabine, or rituximab.

RELATED: Lenalidomide Plus R-ESHAP Feasible for Relapsed, Refractory Lymphoma

Results of the prespecified primary analysis showed that after a median follow-up of 15.9 months, median progression-free survival was 8.7 months (95% CI, 5.5 - 12.1) compared with 5.2 months (95% CI, 3.7 - 6.9) with investigator's choice (HR, 0.61; 95% CI, 0.44 - 0.84; P = .004).

In terms of safety, the most common grade 3 or 4 adverse events were neutropenia (without increased risk of infection), thrombocytopenia, leukopenia, and anemia.

Reference

  1. Trnĕný M, Lamy T, Walewski J, et al. Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial [published online ahead of print February 15, 2016]. Lancet Oncol. doi: 10.1016/S1470-2045(15)00559-8.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters